# Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

> **NCT00492869** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 124 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** AEB071

## Key facts

- **NCT ID:** NCT00492869
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492869, "Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00492869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*